BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 233 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $23,775 | +51.4% | 3,358 | +50.6% | 0.01% | 0.0% |
Q2 2023 | $15,699 | +51.6% | 2,230 | +79.5% | 0.01% | +66.7% |
Q1 2023 | $10,358 | -70.2% | 1,242 | -59.0% | 0.00% | -75.0% |
Q4 2022 | $34,796 | +216.3% | 3,031 | +180.1% | 0.01% | +71.4% |
Q2 2022 | $11,000 | -15.4% | 1,082 | +31.8% | 0.01% | 0.0% |
Q1 2022 | $13,000 | +44.4% | 821 | +20.2% | 0.01% | +75.0% |
Q4 2021 | $9,000 | -10.0% | 683 | -5.1% | 0.00% | -33.3% |
Q3 2021 | $10,000 | -41.2% | 720 | -32.5% | 0.01% | -45.5% |
Q2 2021 | $17,000 | +240.0% | 1,066 | +112.8% | 0.01% | +37.5% |
Q1 2021 | $5,000 | – | 501 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |